publication date: Feb. 16, 2018
Issue 7 - Feb. 16, 2018
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • A confusing Valentine: White House proposes cutting NIH by 27 percent, and—at the same time—reverses the cut

    What a difference a week makes.

    Last week, advocates for biomedical research were bracing for another shutdown of the federal government and fearing that the president’s budget proposal for fiscal year 2019 would drastically slash NIH.

  • NCI Director’s Report

    Sharpless: NCI should increase funding for RPG pool to maintain success rates for R01s

    NCI may need to invest at least $125 million in new money in the Research Project Grant pool in 2018 if the institute plans on keeping the success rates for R01s comparable to 2017, said NCI Director Ned Sharpless.

  • In Brief

    • NCI’s Lowy and Schiller win Szent-Györgyi Prize
    • Aldape starts as chief of laboratory of pathology at the NCI
    • Aghajanian appointed as NRG Oncology Gynecologic Cancer Committee Chair
    • Hudson named co-chair of NRG Oncology Delivery Research Committee
    • AACR’s Cancer Today magazine launches new website

     

  • Funding Opportunities

    American Cancer Society Supports Early Career Clinicians’ Move into Clinical Science

    The American Cancer Society started a grant program to support early career clinicians aiming to become clinician scientists.

  • TCCL Logo

  • Trials and Tribulations

    A Cancer Patient’s War on Cancer

    Imagine a hospital ward 100 years from now. Will multi-drug resistant infections be as prominent as they are today? I suspect so, because as antibiotics evolve, so will the infectious diseases they target. It’s an arms race in which both sides have a capacity to learn and adapt. Not so cancer. Cancers can’t learn from each other. But cancer patients can. This profound imbalance in the capacity for learning is an advantage that all cancer patients share. It is our super power. And we barely use it.

  • Clinical Roundup

    • NCCN & ASCO provide joint guidance on side effects from checkpoint inhibitors
    • Phase II trial shows durvalumab active in recurrent or metastatic head and neck cancer
    • UW Carbone study finds caregiver spouses of cancer patients suffer untreated depression
  • Drugs and Targets

    • FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint
    • Roche to acquire Flatiron Health for $1.9 billion
    • BMS, Nektar form collaboration for CD122-biased agonist
    • Tivozanib gets NICE nod for first-line treatment of advanced RCC

Copyright (c) 2018 The Cancer Letter Inc.